{
  "title": "Paper_1157",
  "abstract": "pmc Int J Mol Sci Int J Mol Sci 808 ijms ijms International Journal of Molecular Sciences 1422-0067 Multidisciplinary Digital Publishing Institute  (MDPI) PMC12469615 PMC12469615.1 12469615 12469615 41009531 10.3390/ijms26188963 ijms-26-08963 1 Communication Molecular Features and Actionable Gene Targets of Testicular Germ Cell Tumors in a Real-World Setting Morales-Grimany Rafael 1 † Giannikou Krinio 2 † Delgado Cesar 2 Pandit Kshitij 2 Baky Fady 3 Amini Armon 3 Yuen Kit 2 https://orcid.org/0000-0002-8877-6799 Gerald Thomas 3 https://orcid.org/0000-0001-6134-1237 Badia Rohit 3 Taylor Jacob 3 Wang Luke 2 Javier-Desloges Juan 2 Margulis Vitaly 3 Woldu Solomon 3 Salmasi Amirali 2 Millard Fred 4 Mckay Rana R. 4 https://orcid.org/0000-0002-3358-1193 Bagrodia Aditya 2 3 * Kzhyshkowska Julia Academic Editor 1 121rmorales@uccaribe.edu 2 kgiannikou@health.ucsd.edu cedelgado@health.ucsd.edu kpandit@health.ucsd.edu k3yuen@health.ucsd.edu llw005@health.ucsd.edu jjavierdesloges@health.ucsd.edu asalmasi@health.ucsd.edu 3 fady.baky@phhs.org armon.amini@utsouthwestern.edu thomas.s.gerald.mil@health.mil rohit.badia@utsouthwestern.edu jacob.taylor.mail@gmail.com vitaly.margulis@utsouthwestern.edu solomon.woldu@utsouthwestern.edu 4 fmillard@health.ucsd.edu rmckay@health.ucsd.edu * bagrodia@health.ucsd.edu † These authors contributed equally to this work. 15 9 2025 9 2025 26 18 497349 8963 09 6 2025 05 9 2025 12 9 2025 15 09 2025 27 09 2025 29 09 2025 © 2025 by the authors. 2025 https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/ Molecular profiling of testicular germ cell tumors (TGCTs) provides critical insights into personalized treatment approaches, particularly for patients with recurrent or treatment-resistant disease. In this study, we retrospectively analyzed clinicopathological and targeted genomic sequencing data from 27 TGCT patients, including 7 seminomas, 19 non-seminomas, and 1 prepubertal type teratoma, across stage I (48%), stage II (41%), and stage III (11%). Tumor samples were obtained from 27 orchiectomies, with additional pathological specimens collected from 16 of these patients during retroperitoneal lymph node dissections (RPLNDs); these included 8 chemotherapy-naïve and 8 post-chemotherapy cases. The median tumor mutational burden (TMB) was 0.5 mutations/Mb, consistent with the low mutation rate typically observed in TGCTs. Somatic mutations and copy number gain alterations were detected in 56% (15/27) of patients, primarily in KRAS KIT PIK3CB n MSH2 MSH6 RB1 BRCA2 chemoresistance seminoma teratoma embryonal carcinoma mutations targeted therapy This research received no external funding. pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes 1. Introduction Testicular germ cell tumors (TGCTs) are the most common malignancy in young men aged 15–34, with a prevalence of 309,202 patients in the United States of America [ 1 2 3 4 The high survival statistics can be attributed to cisplatin-based chemotherapy, which has been the cornerstone of testicular cancer treatment, achieving remarkable success in curing the majority of patients [ 5 5 6 7 8 9 6 7 9 8 10 11 Current advances in genomic technologies, such as DNA sequencing and transcriptomic profiling, have revolutionized cancer research, and the integration of molecular profiling into clinical settings has greatly expanded our understanding of the genomic landscape in many cancers, including TGCTs [ 12 13 Management of TGCTs depends on histologic subtype and clinical stage, with stage I patients having multiple treatment options [ 14 14 14 The objective of this study was to characterize the landscape of somatic alterations in TGCTs using targeted gene sequencing and to determine the potential clinical relevance of these genomic alterations. Specifically, we aimed to identify actionable mutations and evaluate their distribution across histological subtypes, with a focus on understanding the feasibility and implications of precision oncology approaches in this rare tumor type. 2. Results The cohort of 27 TGCT patients analyzed had a median age of 32 years (age range 23–61 years; IQR: 11). Overall, 13 (48%) had stage I GCT, 11 (41%) stage II, and 3 (11%) stage III disease at diagnosis, with a median follow-up of three years. Seven tumors were seminomas, 19 were non-seminoma, and one pre-pubertal type teratoma ( Figure 1 Table 1 Supplementary Table S1 Table 1 Figure 1 Table 1 Figure 1 Supplementary Table S1 TMB had a median value of 0.5 mutations/Mb and a mean of 0.75 mutations/Mb across all TGCT samples. Reflecting the low somatic mutation rate that characterizes TGCTs in general ( Figure 1 KRAS KIT PIK3CB Figure 1 Within our cohort, there were four somatic KRAS KRAS KRAS KRAS KRAS KRAS Four KRAS KRAS KRAS KRAS KRAS KRAS KIT PIK3CB KIT KRAS Additionally, all KIT KIT KIT KIT KIT Table 2 KIT In addition, MSI status was assessed in all 27 patients. The MSI results for four patients were not reported due to <30% tumor content ( Supplementary Table S1 Supplementary Table S1 Within our cohort, we identified ten germline variants of unknown significance (VUS) in nine patients. Most of them were missense, affecting well-established cancer-associated genes such as DNA mismatch repair genes ( MSH2 MSH6 BRCA2 RB1 Table 3 KMT2C MTOR NF1 NF2 Table 3 3. Discussion In this study, we performed targeted gene sequencing and identified key molecular features of TGCTs, including frequent KRAS KIT PIK3CB 19 KIT KRAS 20 21 KRAS KIT 21 KRAS KIT 21 KRAS KRAS KIT PIK3C PIK3CA PIK3CD 21 PIK3CB NRAS KRAS 21 22 The genomic landscape of TGCTs is characterized by a relatively low TMB compared to other solid tumors, with frequent chromosomal abnormalities such as gains in chromosome 12p and loss of heterozygosity in specific regions, e.g., chr1p, 11q, 13q, 18q [ 23 24 KIT KRAS 23 25 2 26 KRAS 27 28 27 28 KRAS 27 28 Another critical reason to identify more specific targets and develop equally effective novel treatments is to address the significant side effect profile posed by bleomycin, etoposide, and platinum. Despite success, chemotherapy is reported to cause significant side effects in more than half of patients [ 29 30 31 32 33 Among the variants of uncertain significance (VUS) identified in this cohort, several were found in genes with known implications for cancer risk and therapeutic response, including BRCA2 MSH2 MSH6 RB1 BRCA2 MSH2 MSH6 Table 3 This study has several limitations. First, we acknowledge the relatively small sample size ( n KIT KRAS In conclusion, this study highlights the molecular heterogeneity of TGCTs across disease clinical states and emphasizes the importance of molecular profiling to identify actionable targets and inform suitable therapeutic strategies, particularly for patients with recurrent, refractory, or treatment-resistant TGCTs. 4. Materials and Methods 4.1. Patient Cohort and Methods Following the Institutional Review Board (IRB#190443) approval of our study, we collated clinicopathological and molecular/genomic data from 27 patients with TGCTs seen at the Department of Urology, University of Southwestern, Texas, between 2018 and 2021. Diagnosis was made based on clinicopathologic/morphologic and immunohistochemical characteristics evaluated by pathologists with expertise in TGCTs according to the 2022 WHO Classification of Germ Cell Tumors [ 34 PMS2 TERT 35 In accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines and the Preferred Reporting of Case Series in Surgery (PROCESS 2023), this was a single-center, retrospective analysis of consecutively sequenced cases seen at UTSW between 2018 and 2021 [ 36 37 The primary outcome of this study was the identification of potentially actionable genomic alterations in TGCTs, defined by the presence of somatic mutations with therapeutic or diagnostic relevance according to OncoKB [ 38 39 4.2. Gene Variant Call Analysis Data from the National Comprehensive Cancer Network Guidelines [ 14 38 39 40 41 42 43 Disclaimer/Publisher’s Note: Supplementary Materials The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms26188963/s1 Author Contributions A.B.: Conceptualized the project and designed the experiments. R.M.-G., K.G. and K.P.: drafted the manuscript. R.M.-G., K.G. and A.B.: Performed analyses and data interpretation, and presentation. A.B.: Provided tumor samples and other biological material. A.B., R.R.M., K.G., K.P., C.D., F.B., A.A., K.Y., L.W., T.G., R.B., J.T., J.J.-D., V.M., S.W., A.S., F.M. and R.R.M.: Critically reviewed the manuscript. F.M., R.R.M. and A.B.: Contributed to project administration. A.B.: Supervised the study. R.M.-G.: Submitted the manuscript. All authors have read and agreed to the published version of the manuscript. Institutional Review Board Statement IRB approved (IRB#190443, 28 May 2025) Collection of Clinical and Biospecimen Data to Assess Predictive and Prognostic Biomarkers in Benign and Malignant Genitourinary (GU) Conditions. Informed Consent Statement Informed consent was obtained from all subjects involved in the study. Data Availability Statement The additional data supporting the manuscript are available from the corresponding author upon request. Conflicts of Interest The authors declare no conflicts of interest. References 1. Cancer of the Testis-Cancer Stat Facts [Internet] SEER Available online: https://seer.cancer.gov/statfacts/html/testis.html (accessed on 10 April 2025) 2. Singh R. Fazal Z. Freemantle S.J. Spinella M.J. Between a Rock and a Hard Place: An Epigenetic-Centric View of Testicular Germ Cell Tumors Cancers 2021 13 1506 10.3390/cancers13071506 33805941 PMC8036638 3. Facts About Testicular Cancer|Testicular Cancer Statistics [Internet] Available online: https://www.cancer.org/cancer/types/testicular-cancer/about/key-statistics.html (accessed on 10 April 2025) 4. Lobo J. Acosta A.M. Netto G.J. Molecular Biomarkers with Potential Clinical Application in Testicular Cancer Mod. Pathol. 2023 36 100307 10.1016/j.modpat.2023.100307 37611872 5. Lobo J. Jerónimo C. Henrique R. Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives Cancers 2020 12 1601 10.3390/cancers12061601 32560427 PMC7352163 6. Mao S. Huang S. Zinc and Copper Levels in Bladder Cancer: A Systematic Review and Meta-Analysis Biol. Trace Elem. Res. 2013 153 5 10 10.1007/s12011-013-9682-z 23640281 7. Nunes S.C. Serpa J. Glutathione in Ovarian Cancer: A Double-Edged Sword Int. J. Mol. Sci. 2018 19 1882 10.3390/ijms19071882 29949936 PMC6073569 8. Yan F. Pang J. Peng Y. Molina J.R. Yang P. Liu S. Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells PLoS ONE 2016 11 e0162925 10.1371/journal.pone.0162925 27610620 PMC5017656 9. Hsu W.H. Zhao X. Zhu J. Kim I.K. Rao G. McCutcheon J. Hsu S.-T. Teicher B. Kallakury B. Dowlati A. Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death J. Thorac. Oncol. 2019 14 1032 1045 10.1016/j.jtho.2019.01.028 30771522 PMC6534433 10. de Vries G. Rosas-Plaza X. van Vugt M.A.T.M. Gietema J.A. de Jong S. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities Cancer Treat. Rev. 2020 88 102054 10.1016/j.ctrv.2020.102054 32593915 11. Elmorsy E.A. Saber S. Hamad R.S. Abdel-Reheim M.A. El-kott A.F. AlShehri M.A. Morsy K. Salama S.A. Youssef M.E. Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies Eur. J. Pharm. Sci. 2024 203 106939 10.1016/j.ejps.2024.106939 39423903 12. Baroni T. Arato I. Mancuso F. Calafiore R. Luca G. On the Origin of Testicular Germ Cell Tumors: From Gonocytes to Testicular Cancer Front. Endocrinol. 2019 10 343 10.3389/fendo.2019.00343 PMC6563414 31244770 13. De Toni L. Šabovic I. Cosci I. Ghezzi M. Foresta C. Garolla A. Testicular Cancer: Genes, Environment, Hormones Front. Endocrinol. 2019 10 408 10.3389/fendo.2019.00408 PMC6626920 31338064 14. Gilligan T. Lin D.W. Adra N. Bagrodia A. Feldman D.R. Yamoah K. Aggarwal R. Chandrasekar T. Costa D. Drakaki A. NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025: Featured Updates to the NCCN Guidelines J. Natl. Compr. Cancer Netw. 2025 23 e250018 10.6004/jnccn.2025.0018 40203876 15. Richards S. Aziz N. Bale S. Bick D. Das S. Gastier-Foster J. Grody W.W. Hegde M. Lyon E. Spector E. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Genet Med. 2015 17 405 424 10.1038/gim.2015.30 25741868 PMC4544753 16. Tate J.G. Bamford S. Jubb H.C. Sondka Z. Beare D.M. Bindal N. Boutselakis H. Cole C.G. Creatore C. Dawson E. COSMIC: The Catalogue of Somatic Mutations in Cancer Nucleic Acids Res. 2019 47 D941 D947 10.1093/nar/gky1015 30371878 PMC6323903 17. Kopanos C. Tsiolkas V. Kouris A. Chapple C.E. Albarca Aguilera M. Meyer R. Massouras A. VarSome: The human genomic variant search engine Bioinformatics 2019 35 1978 1980 10.1093/bioinformatics/bty897 30376034 PMC6546127 18. Landrum M.J. Lee J.M. Benson M. Brown G.R. Chao C. Chitipiralla S. Gu B. Hart J. Hoffman D. Jang W. ClinVar: Improving access to variant interpretations and supporting evidence Nucleic Acids Res. 2018 46 D1062 D1067 10.1093/nar/gkx1153 29165669 PMC5753237 19. Cabral E.R.M. Pacanhella M.F. Lengert A.V.H. Reis M.B.D. Leal L.F. Lima M.A.D. da Silva A.L.V. Pinto I.A. Reis R.M. Pinto M.T. Somatic mutation detection and KRAS amplification in testicular germ cell tumors Front. Oncol. 2023 13 1133363 10.3389/fonc.2023.1133363 37007070 PMC10060882 20. Cárcano F.M. Lengert A.H. Vidal D.O. Scapulatempo Neto C. Queiroz L. Marques H. Baltazar F. Berardinelli G. Martinelli C.M.S. da Silva E.C.A. Absence of microsatellite instability and BRAF V600E Andrology 2016 4 866 872 10.1111/andr.12200 27153176 21. Shen H. Shih J. Hollern D.P. Wang L. Bowlby R. Tickoo S.K. Mungall A.J. Newton Y. Hegde A.M. Armenia J. Integrated Molecular Characterization of Testicular Germ Cell Tumors Cell Rep. 2018 23 3392 3406 10.1016/j.celrep.2018.05.039 29898407 PMC6075738 22. Fankhauser C.D. Curioni-Fontecedro A. Allmann V. Beyer J. Tischler V. Sulser T. Moch H. Bode P.K. Frequent PD-L1 expression in testicular germ cell tumors Br. J. Cancer 2015 113 411 413 10.1038/bjc.2015.244 26171934 PMC4522642 23. Hacioglu B.M. Kodaz H. Erdogan B. Cinkaya A. Tastekin E. Hacibekiroglu I. Turkmen E. Kostek O. Genc E. Uzunoglu S. K-RAS and N-RAS mutations in testicular germ cell tumors Bosn. J. Basic Med. Sci. 2017 17 159 163 10.17305/bjbms.2017.1764 28426398 PMC5474110 24. Ní Leathlobhair M. Frangou A. Kinnersley B. Cornish A.J. Chubb D. Lakatos E. Arumugam P. Gruber A.J. Law P. Tapinos A. Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project Nat. Commun. 2024 15 9247 10.1038/s41467-024-53193-6 39461959 PMC11513037 25. Stephenson A. Eggener S.E. Bass E.B. Chelnick D.M. Daneshmand S. Feldman D. Gilligan T. Karam J.A. Leibovich B. Liauw S.L. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline J. Urol. 2019 202 272 281 10.1097/JU.0000000000000318 31059667 26. Ou X. Gao G. Habaz I.A. Wang Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies MedComm (2020) 2024 5 e694 10.1002/mco2.694 39184861 PMC11344283 27. De Roock W. Claes B. Bernasconi D. De Schutter J. Biesmans B. Fountzilas G. Kalogeras K.T. Kotoula V. Papamichael D. Laurent-Puig P. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis Lancet Oncol. 2010 11 753 762 10.1016/S1470-2045(10)70130-3 20619739 28. Meric-Bernstam F. Hurwitz H. Raghav K.P.S. McWilliams R.R. Fakih M. VanderWalde A. Swanton C. Kurzrock R. Burris H. Sweeney C. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study Lancet Oncol. 2019 20 518 530 10.1016/S1470-2045(18)30904-5 30857956 PMC6781620 29. Khan M.R. Sheehan P.K. Bazin A. Leonard C. Aleem U. Corrigan L. McDermott R. Late side effects of testicular cancer and treatment: A comprehensive review Discov. Oncol. 2024 15 646 10.1007/s12672-024-01549-1 39532799 PMC11557811 30. Lubberts S. Meijer C. Demaria M. Gietema J.A. Early ageing after cytotoxic treatment for testicular cancer and cellular senescence: Time to act Crit. Rev. Oncol./Hematol. 2020 151 102963 10.1016/j.critrevonc.2020.102963 32446180 31. Hiester A. Che Y. Lusch A. Kuß O. Niegisch G. Lorch A. Arsov C. Albers P. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST) Eur. Urol. 2023 84 25 31 10.1016/j.eururo.2022.10.021 36372627 32. Daneshmand S. Cary C. Masterson T. Einhorn L. Adra N. Boorjian S.A. Kollmannsberger C. Schuckman A. So A. Black P. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy J. Clin. Oncol. 2023 41 3009 3018 10.1200/JCO.22.00624 36913642 33. Heidenreich A. Paffenholz P. Hartmann F. Seelemeyer F. Pfister D. Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS) Eur. Urol. Oncol. 2024 7 122 127 10.1016/j.euo.2023.06.004 37438222 34. Berney D.M. Cree I. Rao V. Moch H. Srigley J.R. Tsuzuki T. Amin M.B. Comperat E.M. Hartmann A. Menon S. An introduction to the WHO 5th edition 2022 classification of testicular tumours Histopathology 2022 81 459 466 10.1111/his.14675 35502823 PMC9544657 35. Beaubier N. Tell R. Lau D. Parsons J.R. Bush S. Perera J. Sorrells S. Baker T. Chang A. Michuda J. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay Oncotarget 2019 10 2384 2396 10.18632/oncotarget.26797 31040929 PMC6481324 36. STROBE [Internet] STROBE Available online: https://www.strobe-statement.org/ (accessed on 13 July 2025) 37. Agha R. Mathew G. Rashid R. Kerwan A. Al-Jabir A. Sohrabi C. Franchi T. Nicola M. Agha M. PROCESS Group Revised Preferred Reporting of Case Series in Surgery (PROCESS) Guideline: An update for the age of Artificial Intelligence Prem. J. Sci. 2025 10 100080 10.70389/PJS.100080 38. Suehnholz S.P. Nissan M.H. Zhang H. Kundra R. Nandakumar S. Lu C. Carrero S. Dhaneshwar A. Fernandez N. Xu B.W. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer Cancer Discov. 2024 14 49 65 10.1158/2159-8290.CD-23-0467 37849038 PMC10784742 39. Chakravarty D. Gao J. Phillips S. Kundra R. Zhang H. Wang J. Rudolph J.E. Yaeger R. Soumerai T. Nissan M.H. OncoKB: A Precision Oncology Knowledge Base JCO Precis. Oncol. 2017 1 1 16 10.1200/PO.17.00011 PMC5586540 28890946 40. Sim N.L. Kumar P. Hu J. Henikoff S. Schneider G. Ng P.C. SIFT web server: Predicting effects of amino acid substitutions on proteins Nucleic Acids Res. 2012 40 W452 W457 10.1093/nar/gks539 22689647 PMC3394338 41. Choi Y. Chan A.P. PROVEAN web server: A tool to predict the functional effect of amino acid substitutions and indels Bioinformatics 2015 31 2745 2747 10.1093/bioinformatics/btv195 25851949 PMC4528627 42. Chengsheng T. Huacheng L. Bing X. AdaBoost typical Algorithm and its application research MATEC Web Conf. 2017 139 00222 10.1051/matecconf/201713900222 43. Cutler A. Cutler D.R. Stevens J.R. Random Forests Ensemble Machine Learning Zhang C. Ma Y. Springer New York, NY, USA 2012 157 175 Available online: https://link.springer.com/10.1007/978-1-4419-9326-7_5 (accessed on 13 July 2025) Figure 1 Molecular and clinicopathological overview of testicular germ cell tumors (TGCTs) in a real-world cohort ( n A B C p D KRAS KIT PIK3CB ijms-26-08963-t001_Table 1 Table 1 Clinicopathological data in the Testicular Cancer Cohort. Clinicopathological Variables Number of Patients (%) Clinical disease stage I 13 (48) II 11 (41) III 3 (11) Type of TGCT Seminoma 7 (26) Non-Seminoma 19 (70) Pre-pubertal teratoma 1 (4) Surgeries Performed Orchiectomy 27 (100)  RPLND 16 (59) Chemotherapy status prior RPLND Chemotherapy-naïve 8 (50) Post-chemotherapy 8 (50) RPLND: Retroperitoneal Lymph Node Dissection. ijms-26-08963-t002_Table 2 Table 2 Summary of pathogenic somatic variants identified in the testicular tumor cohort according to Tempus. Patient ID Gene AA Change Alteration Effect Function Variant Allele Frequency Mutations/MB TGCT-1  BCOR p.S177fs Frameshift LOF 10.50% 1.6 TGCT-2  KIT p.N822K # Missense GOF 8.10% 1.6  PIK3CB p.E1051K Missense GOF 8.60% TGCT-3  KRAS p.G12R Missense GOF 4.00% 1.6  PIK3CB p.E1051K Missense GOF 8.60% TGCT-6  KIT p.D816V # Missense GOF 12.70% 1.7 TGCT-7  KDR -- Copy number gain -- -- 0.4  KIT -- Copy number gain -- -- p.N822K # Missense GOF 39.36%  KRAS -- Copy number gain -- -- TGCT-8  KRAS p.G12C Missense GOF 59.70% 3.7 TGCT-10  KRAS p.G12V Missense GOF 29.40% 0.8 TGCT-12  GRIN2A -- Copy number loss -- -- 0.0  MCL1 -- Copy number gain -- -- TGCT-14  TP53 p.L252_I254del Inframe deletion LOF 16.60% 0.5 TGCT-18  ETV1 -- Copy number gain -- -- 0.8  FGFR1 -- Copy number gain -- --  JUN -- Copy number gain -- --  KRAS -- Copy number gain -- --  NCOR1 p.Stgc43 Stop codon LOF 2.12% TGCT-21  DDX3X p.766-1G>T Splice region LOF 4.90% 0.0  KMT2D p.G5189 * Stop codon LOF 2.90%  MAP3K1 p.G331 * Stop codon LOF 3.70% TGCT-24  CCND2 -- Copy number gain -- -- 0.8  CHD4 -- Copy number gain -- --  KDM5A -- Copy number gain -- --  KRAS -- Copy number gain -- -- p.G12D Missense GOF 59.30% TGCT-25  KRAS -- Copy number gain -- -- 0.4 TGCT-26  ASXL1 p.E565fs Frameshift LOF 16.56% 0.4 TGCT-27  FAT1 p.L1889fs Frameshift LOF 24.65% 2.9 LOF: loss of function, GOF: gain of function, AA: amino acid, # ijms-26-08963-t003_Table 3 Table 3 Summary of variants of unknown significance (VUS) identified in 32 genes in the testicular tumor cohort. Patient ID Type of Variant Gene AA Alteration Variant Effect Variant Allele Frequency ACMG Classification TGCT-1 Somatic  PRKN p.L102F Missense 9.7% VUS Somatic  RANBP2 p.P162A Missense 15.2% VUS TGCT-2 Somatic  C8orf34 p.L523del Inframe deletion 6.9% VUS Germline  MSH6 p.T999P Missense N.A. Likely Pathogenic Germline  PMS2 p.Q160H Missense N.A. VUS TGCT-3 Somatic  KEL p.H581P Missense 6.2% VUS Germline  PALB2 p.V836I Missense N.A. Likely Pathogenic TGCT-4 Somatic  FAM46C p.N18S Missense 5.4% N.A TGCT-6 Somatic  KMT2C p.C3460G Missense 9.1% Likely Pathogenic Somatic  MAF p.H187del Inframe deletion 6.0% VUS Somatic  MTOR p.K1981E Missense 12.8% Likely Pathogenic TGCT-7 Germline  MUTYH p.L420M Missense N.A. Pathogenic TGCT-10 Germline  RET p.R180Q Missense N.A. VUS TGCT-11 Germline  APOB p.Y3295H Missense N.A. VUS Germline  MSH6 p.P66L Missense N.A. Likely Pathogenic Somatic  NF1 p.L762M Missense 13.9% Likely Pathogenic TGCT-13 Somatic  CUX1 p.R1374L Missense 10.4% N.A Somatic  KMT2D p.R1918P Missense 12.1% N.A TGCT-15 Somatic  ERBB2 p.E992K Missense 25.9% Pathogenic TGCT-16 Germline  APOB p.M1150K Missense N.A. N.A Germline  BRCA2 p.F2058I Missense N.A. N.A Germline  RB1 p.E137D Missense N.A. N.A TGCT-17 Germline  BRCA2 p.Q2858K Missense N.A. N.A TGCT-18 Somatic  NF2 p.T581I Missense 25.5% Likely Pathogenic TGCT-20 Somatic  IL7R p.G424V Missense 7.4% N.A TGCT-24 Germline  APOB p.G753E Missense N.A. N.A Germline  APOB p.Y129C Splice site N.A. N.A Somatic  JAK3 p.R210W Missense 27.8% Likely Pathogenic Germline  MSH2 p.L119S Missense N.A. N.A Germline  MSH6 p.E277D Missense N.A. N.A TGCT-25 Somatic  GRM3 p.C127Y Missense 15.3% VUS TGCT-26 Germline  RET p.E623K Missense N.A. N.A TGCT-27 Somatic  HSP90AA1 p.V266I Missense 17.4% N.A Somatic  RUNX1 p.S167I Missense 20.5% N.A Somatic  WRN p.Q253 * Stop codon 28.3% Pathogenic AA: amino acid, N.A: not applicable. *: Stop codon. Germline classification was assigned based on the ACMG guidelines [ 15 16 17 18 ",
  "metadata": {
    "Title of this paper": "Random Forests",
    "Journal it was published in:": "International Journal of Molecular Sciences",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469615/"
  }
}